

PATENT

Attorney Docket No. 227833 Client Reference No. JF-133US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Sunami et al.

Group Art Unit: 1614

Application No. 10/802,220

Examiner: Unassigned

Filed: March 17, 2004

For: PHARMACEUTICAL COMPOSITIONS OF CETP INHIBITORS

INFORMATION DISCLOSURE STATEMENT

Mail Stop Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Pursuant to 37 CFR 1.97 and 1.98, the references listed on the enclosed Form PTO-1449 and/or Substitute Form PTO-1449 ("Form 1449") are submitted for consideration by the Examiner in the examination of the above-identified patent application.

The full consideration of the references in their entirety by the Examiner is respectfully requested and encouraged. Also, it is respectfully requested that the references be entered into the record of the present application and that the Examiner place his or her initials in the appropriate area on the enclosed Form 1449, thereby indicating the Examiner's consideration of each of the references.

The submission of the references listed on the Form 1449 is for the purpose of providing a complete record and is not a concession that the references listed thereon are prior art to the invention claimed in the patent application. The right is expressly reserved to establish an invention date earlier than the above-identified filing date in order to remove any reference submitted herewith as prior art should it be deemed appropriate to do so.

Further, the submission of the references is not to be taken as a concession that any reference represents art that is relevant or analogous to the claimed invention. Accordingly, the right to argue that any reference is not properly within the scope of prior art relevant to an examination of the claims in the above-identified application is also expressly reserved.

The Information Disclosure Statement is being filed:

within any one of the following time periods: (a) within three months of the filing date of a national application other than a continued prosecution application under 37 CFR 1.53(d); (b) within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 of an international application; (c) before the mailing date of a first Office Action on the merits; or (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

In re Appln. of Sunami et al. Application No. 10/802,220

	after (a), (b), (c) or (d) above, but before the mailing date of a final action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and includes <i>one</i> of:						
		the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below).					
	\Box	the fee of \$180 set forth in 37 CFR 1.17(p) (see "Fees" below).					
	under and o 37 CF	he mailing date of a final action under 37 CFR 1.113 or a Notice of Allowance 37 CFR 1.311, or an action that otherwise closes prosecution in the application, n or before payment of the issue fee, and includes the Statement under R 1.97(e) (see "Statement under 37 CFR 1.97(e)" below), and the fee of \$180 as th in 37 CFR 1.17(p) (see "Fees" below).					
	payme contain 37 CF \$180 a NOTE: May 29	the mailing date of a Notice of Allowance under 37 CFR 1.311, and on or before ent of the issue fee, and within thirty days of receiving each item of information ned in the Information Disclosure Statement, and includes the Statement under R 1.704(d) (see "Statement under 37 CFR 1.704(d)" below), and the fee of its set forth in 37 CFR 1.17(p) (see "Fees" below). This is for original applications except applications for a design patent, filed on or after a 2000, wherein a paper containing only an Information Disclosure Statement in compliance CFR 1.97 and 1.98 is being filed.					
Copie	s of the	References					
	Copies	s of all of the references listed on the enclosed Form 1449 are enclosed ith.					
\boxtimes	Form	s of U.S. patents and patent applications that are listed on the accompanying 1449 are not enclosed herewith. Copies of other references identified on the panying Form 1449 are enclosed herewith.					
\boxtimes	relevation action degree	ned to each reference not in the English language is a concise explanation of the nce pursuant to 37 CFR 1.98(a)(3). An English-language equivalent/patent, or glish-language abstract, or an English-language version of the search report or by a foreign patent office in a counterpart foreign application indicating the of relevance found by the foreign office is being submitted in lieu of a concise nation of the relevance pursuant to 37 CFR 1.98(a)(3).					
\boxtimes		by of the foreign search report associated with International Application No. JP04/003585 is enclosed herewith.					
		eferences listed on the enclosed Form 1449 were previously identified in the application(s) of the present application, and copies of the references were					

In re Appln. of Sunami et al. Application No. 10/802,220

furnished at that time. Accordingly, additional copies of the references are not submitted herewith, so as not to burden the file with duplicate copies of references. The Examiner is respectfully requested to carefully review the references in accordance with the requirements set out in the Manual of Patent Examining Procedure. In accordance with 37 CFR 1.98(d), the details of the parent application(s) relied upon for an earlier filing date under 35 USC 120 in which copies of the references were previously furnished are set out below:

U.S. APPLI	CATIONS	Status (check one)			
U.S. APPLICATIONS	U.S. FILING DATE	PATENTED	PENDING ABANDO		
1.					
2.					
3.					

Statement under 37 CFR 1.97(e) The undersigned hereby states that each item of information contained in the

Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.

The **undersigned** hereby states that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.


Statement under 37 CFR 1.704(d)

The undersigned hereby states that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 CFR 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.

Fees

П

No fee is owed by the applicant(s).
The IDS Fee of \$180 under 37 CFR 1.17(p) is enclosed herewith.



Metho	od of Payment of Fees						
	Attached is a check in the amount of \$. Charge Deposit Account No. 12-1216 in the amount of \$. (A duplicate copy of this communication is enclosed for that purpose.)						
Autho	orization to Charge Additional Fees						
\boxtimes	If any additional fees are owed in connection with this communication, please charge Deposit Account No. 12-1216. (A duplicate copy of this communication is enclosed for that purpose.)						
Instru	ctions as to Overpayment						
	Credit Account No. 12-1216. Refund John Kilyk, Jr., Reg. No. 39,763 LEYDIG, VOIT & MAYER, LTD. Two Prudential Plaza, Suite 4900 180 North Stetson Avenue Chicago, Illinois 60601-6780 (312) 616-5600 (telephone) (312) 616-5700 (facsimile)						

CERTIFICATE OF MAILING

I hereby certify that this INFORMATION DISCLOSURE STATEMENT (along with any documents referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Mail Stop, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: December 8, 2004

Date: December 8, 2004

Substitute for form 1449A/B/PTO

INFORMATION DISCLASURE STATEMENT BY APPLICANT

DEC 1 3 2004

(Use as many sheets as necessary)

Sheet 1 of	
------------	--

Complete if Known					
Application Number	10/802,220				
Filing Date	Mar. 17, 2004				
First Named Inventor	Sunami et al.				
Group Art Unit	1614				
Examiner Name	Unassigned				
Attorney Docket Number	227833				
Client Reference Number	JF-133US				

	-			U.S. PATENT DOCUMENTS		
U.S. Patent Document						
Examiner Initials	Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
	FH	10/802,280		Urata et al.		Mar. 17, 2004
	FI	10/825,531		Shinkai et al.		Apr. 15, 2004
	FJ	10/835,916		Urata et al.		Apr. 30, 2004
•						
-						
÷						

				FORE	IGN PATENT DOCUMENTS			
		Foreign Patent Document		t			Translation	
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No*+
	FK	EP	0 992 496	A1	PFIZER PRODUCTS INC.	Apr. 12, 2000		
	FL	EP	1 269 994	A2	PFIZER PRODUCTS INC.	Jan. 2, 2003		
	FM	wo	00/17164	A1	PFIZER PRODUCTS INC.	Mar. 30, 2000		
	FN	WO	03/000235	A1	PFIZER PRODUCTS INC.	Jan. 3, 2003		
	FO	wo	03/063832	A1	PFIZER PRODUCTS INC.	Aug. 7, 2003		
	FP	WO	2004/082593	A2	JAPAN TOBACCO INC.	Sep. 30, 2004		
	FQ	WO	2004/082675	A1	JAPAN TOBACCO INC.	Sep. 30, 2004		
	FR	WO	2004/098583	A1	JAPAN TOBACCO INC.	Nov. 18, 2004		

	OTHER - NON PATENT LITERATURE DOCUMENTS						
Examiner	Doc.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	Translation				
Initials	No.	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.		No**			
			-				

Examiner Signature	Date Considered .

^{*} A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

⁺ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).